Cellectis (CLLS) Shareholder's Equity Growth (3y) (2017 - 2026)
Cellectis (CLLS) Shareholder's Equity Growth (3y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-20.77% |
| Dec 31, 2025 |
-15.53% |
| Sep 30, 2025 |
-11.63% |
| Jun 30, 2025 |
-18.67% |
| Mar 31, 2025 |
-16.98% |
| Dec 31, 2024 |
-17.86% |
| Sep 30, 2024 |
-20.96% |
| Jun 30, 2024 |
-21.08% |
| Mar 31, 2024 |
-32.13% |
| Dec 31, 2023 |
-35.03% |
| Sep 30, 2023 |
-38.43% |
| Jun 30, 2023 |
-34.59% |
| Mar 31, 2023 |
-31.24% |
| Dec 31, 2022 |
-26.34% |
| Sep 30, 2022 |
-27.48% |
| Jun 30, 2022 |
-23.62% |
| Mar 31, 2022 |
-22.27% |
| Dec 31, 2021 |
-16.71% |
| Sep 30, 2021 |
-17.76% |
| Jun 30, 2021 |
-14.80% |
